Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Innoskel logo — Developing novel therapies for rare bone diseases

Innoskel

Developing novel therapies for rare bone diseases

Founded 2020 France France 2 employees Series A Total: $20.00M Biotechnology, Health and Wellness

General Information

Company Name Innoskel
Founded Year 2020
Location France France
Founders / Decision Makers
Team member
Employees 2
Industries Biotechnology, Health and Wellness
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Innoskel. To contact Innoskel, visit innoskel.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Innoskel compare?

A PDF of Innoskel and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Innoskel soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Innoskel

Innoskel is a biotechnology startup with the slogan "Developing novel therapies for rare bone diseases." Founded in 2020 and headquartered in France, the company is focused on developing therapies for rare bone diseases, particularly targeting type 2 collagenopathies, including Spondyloepiphyseal Dysplasia congenita (SEDc), which is the second leading cause of dwarfism worldwide. Innoskel’s lead gene therapy asset for SEDc has shown promising efficacy in proof-of-concept studies. The company's last investment was a €20.00M Series A investment on 14 December 2020, with participation from Jeito Capital, Turenne Capital, Vida Ventures, and Région Sud Investissement. Innoskel's fundamental mission revolves around improving the lives of patients living with rare bone disorders, with a focus on addressing their unmet needs and placing their voices at the heart of all strategic decisions. The startup operates within the Biotechnology and Health and Wellness industries, aiming to make a significant impact in the field of rare bone disease therapies.

Business keywords: Rare diseases, Therapeutic development, Type 2 collagenopathies, Gene therapy, Skeletal disorders, Proof-of-concept studies, Spin-out, Medical research, Institut de Biology Valrose, Therapeutic innovation

Services & Products

Online retail of a wide range of products including electronics
fashion
beauty and health
home and lifestyle
sports and outdoor
automotive
gaming
electronics accessories

Target Customers

Consumers seeking a diverse range of products for online purchase across various categories.

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A €20.00M 4
Jeito Capital Turenne Capital Vida Ventures
Jeito Capital, Turenne Capital +2
14 Dec 2020

Innoskel Alternatives & Competitors

View All Alternatives
Innoskel vs
Axovia Therapeutics
Axovia Therapeutics United Kingdom

Driving gene therapy breakthroughs to develop transformative AAV treatments for patients with ciliop...

7 employees
Biopharma, Biotechnology
Innoskel vs
Benitec Biopharma Inc.
Benitec Biopharma Inc. United States

Silencing genes for life

Post-IPO Equity
16 employees
Biotechnology, Health Care
Innoskel vs
AAVantgarde
AAVantgarde

Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease

Series A
70 employees
Biotechnology, Health Care
View all alternatives

FAQ About Innoskel

Developing novel therapies for rare bone diseases
Innoskel was founded in 2020.
Innoskel is headquartered in France.
Innoskel operates in Biotechnology and Health and Wellness. Its work centres on Rare diseases, Therapeutic development, Type 2 collagenopathies and Gene therapy. Its customers include Consumers seeking a diverse range of products for online purchase across various categories..
Innoskel has approximately 2 employees.
Innoskel has completed 1 funding round, raising a total of $20.00M. The latest funding stage is Series A.
Innoskel offers: Online retail of a wide range of products including electronics, fashion, beauty and health, home and lifestyle, sports and outdoor, automotive, gaming, electronics accessories, media and books, and food and beverages..
Top alternatives and competitors to Innoskel include Axovia Therapeutics, Benitec Biopharma Inc., AAVantgarde, Therachon, VeonGen Therapeutics GmbH. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Innoskel and Axovia Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Innoskel, https://bouncewatch.com/company/innoskel, updated 7 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes